Applications of bioorthogonal chemistry in tumor-targeted drug discovery

Gang Liu, Eric A. Wold, Jia Zhou

Research output: Contribution to journalArticle

Abstract

Chemical reactions that can proceed in living systems while not interfering with native biochemical processes are collectively referred to as bioorthogonal chemistry. Selectivity, efficiency, and aqueous compatibility are three significant characteristics of an ideal bioorthogonal reaction. To date, the specialized bioorthogonal reactions that have been reported include: Cu (I)-catalyzed [3 + 2] azido– alkyne cycloadditions (CuAAC), strain-promoted [3 + 2] azide–alkyne cycloadditions (SPAAC), Staudinger ligation, photo-click 1,3-dipolar cycloadditions, strain-promoted alkyne-nitrone cycloadditions (SPANC), transition metal catalysis (TMC), and inverse electron demand Diels–Alder (IEDDA). These reactions are divided into two subtypes, 1) bond-formation reactions (e.g. CuAAC, SPAAC, photo-click cycloadditions, SPANC), which can be conventionally applied in the chemical biology field for target identification, protein-specific modifications and others; and 2) bond-release reactions (e.g. Staudinger ligation, TMC, and IEDDA), which are emerging as powerful approaches for the study of protein activation and drug discovery. Over the past decade, bioorthogonal chemistry has enabled important compound design features in targeted drug discovery and has expanded biological knowledge on intractable targets. Research groups have also focused on the discovery of reactions with improved biocompatibility and increased reaction rates, which will undoubtably prove essential for future therapeutic development. Herein, we highlight two significant applications of bioorthogonal chemistry to drug discovery, which are tumor-targeted prodrug delivery and activation, and self-assembly of bifunctional molecules. The relevant challenges and opportunities are also discussed.

Original languageEnglish (US)
Pages (from-to)892-897
Number of pages6
JournalCurrent topics in medicinal chemistry
Volume19
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cycloaddition Reaction
Drug Discovery
Alkynes
Neoplasms
Catalysis
Ligation
Biochemical Phenomena
Metals
Electrons
Prodrugs
Proteins
Research

Keywords

  • Bifunctional molecules
  • Bioorthogonal Chemistry
  • Chemical reactions
  • Protein activation
  • Tumor-targeted drug discovery

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Applications of bioorthogonal chemistry in tumor-targeted drug discovery. / Liu, Gang; Wold, Eric A.; Zhou, Jia.

In: Current topics in medicinal chemistry, Vol. 19, No. 11, 01.01.2019, p. 892-897.

Research output: Contribution to journalArticle

@article{8f955eae71744c979279b00e3dcffd44,
title = "Applications of bioorthogonal chemistry in tumor-targeted drug discovery",
abstract = "Chemical reactions that can proceed in living systems while not interfering with native biochemical processes are collectively referred to as bioorthogonal chemistry. Selectivity, efficiency, and aqueous compatibility are three significant characteristics of an ideal bioorthogonal reaction. To date, the specialized bioorthogonal reactions that have been reported include: Cu (I)-catalyzed [3 + 2] azido– alkyne cycloadditions (CuAAC), strain-promoted [3 + 2] azide–alkyne cycloadditions (SPAAC), Staudinger ligation, photo-click 1,3-dipolar cycloadditions, strain-promoted alkyne-nitrone cycloadditions (SPANC), transition metal catalysis (TMC), and inverse electron demand Diels–Alder (IEDDA). These reactions are divided into two subtypes, 1) bond-formation reactions (e.g. CuAAC, SPAAC, photo-click cycloadditions, SPANC), which can be conventionally applied in the chemical biology field for target identification, protein-specific modifications and others; and 2) bond-release reactions (e.g. Staudinger ligation, TMC, and IEDDA), which are emerging as powerful approaches for the study of protein activation and drug discovery. Over the past decade, bioorthogonal chemistry has enabled important compound design features in targeted drug discovery and has expanded biological knowledge on intractable targets. Research groups have also focused on the discovery of reactions with improved biocompatibility and increased reaction rates, which will undoubtably prove essential for future therapeutic development. Herein, we highlight two significant applications of bioorthogonal chemistry to drug discovery, which are tumor-targeted prodrug delivery and activation, and self-assembly of bifunctional molecules. The relevant challenges and opportunities are also discussed.",
keywords = "Bifunctional molecules, Bioorthogonal Chemistry, Chemical reactions, Protein activation, Tumor-targeted drug discovery",
author = "Gang Liu and Wold, {Eric A.} and Jia Zhou",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1568026619666190510091921",
language = "English (US)",
volume = "19",
pages = "892--897",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Applications of bioorthogonal chemistry in tumor-targeted drug discovery

AU - Liu, Gang

AU - Wold, Eric A.

AU - Zhou, Jia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chemical reactions that can proceed in living systems while not interfering with native biochemical processes are collectively referred to as bioorthogonal chemistry. Selectivity, efficiency, and aqueous compatibility are three significant characteristics of an ideal bioorthogonal reaction. To date, the specialized bioorthogonal reactions that have been reported include: Cu (I)-catalyzed [3 + 2] azido– alkyne cycloadditions (CuAAC), strain-promoted [3 + 2] azide–alkyne cycloadditions (SPAAC), Staudinger ligation, photo-click 1,3-dipolar cycloadditions, strain-promoted alkyne-nitrone cycloadditions (SPANC), transition metal catalysis (TMC), and inverse electron demand Diels–Alder (IEDDA). These reactions are divided into two subtypes, 1) bond-formation reactions (e.g. CuAAC, SPAAC, photo-click cycloadditions, SPANC), which can be conventionally applied in the chemical biology field for target identification, protein-specific modifications and others; and 2) bond-release reactions (e.g. Staudinger ligation, TMC, and IEDDA), which are emerging as powerful approaches for the study of protein activation and drug discovery. Over the past decade, bioorthogonal chemistry has enabled important compound design features in targeted drug discovery and has expanded biological knowledge on intractable targets. Research groups have also focused on the discovery of reactions with improved biocompatibility and increased reaction rates, which will undoubtably prove essential for future therapeutic development. Herein, we highlight two significant applications of bioorthogonal chemistry to drug discovery, which are tumor-targeted prodrug delivery and activation, and self-assembly of bifunctional molecules. The relevant challenges and opportunities are also discussed.

AB - Chemical reactions that can proceed in living systems while not interfering with native biochemical processes are collectively referred to as bioorthogonal chemistry. Selectivity, efficiency, and aqueous compatibility are three significant characteristics of an ideal bioorthogonal reaction. To date, the specialized bioorthogonal reactions that have been reported include: Cu (I)-catalyzed [3 + 2] azido– alkyne cycloadditions (CuAAC), strain-promoted [3 + 2] azide–alkyne cycloadditions (SPAAC), Staudinger ligation, photo-click 1,3-dipolar cycloadditions, strain-promoted alkyne-nitrone cycloadditions (SPANC), transition metal catalysis (TMC), and inverse electron demand Diels–Alder (IEDDA). These reactions are divided into two subtypes, 1) bond-formation reactions (e.g. CuAAC, SPAAC, photo-click cycloadditions, SPANC), which can be conventionally applied in the chemical biology field for target identification, protein-specific modifications and others; and 2) bond-release reactions (e.g. Staudinger ligation, TMC, and IEDDA), which are emerging as powerful approaches for the study of protein activation and drug discovery. Over the past decade, bioorthogonal chemistry has enabled important compound design features in targeted drug discovery and has expanded biological knowledge on intractable targets. Research groups have also focused on the discovery of reactions with improved biocompatibility and increased reaction rates, which will undoubtably prove essential for future therapeutic development. Herein, we highlight two significant applications of bioorthogonal chemistry to drug discovery, which are tumor-targeted prodrug delivery and activation, and self-assembly of bifunctional molecules. The relevant challenges and opportunities are also discussed.

KW - Bifunctional molecules

KW - Bioorthogonal Chemistry

KW - Chemical reactions

KW - Protein activation

KW - Tumor-targeted drug discovery

UR - http://www.scopus.com/inward/record.url?scp=85071047835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071047835&partnerID=8YFLogxK

U2 - 10.2174/1568026619666190510091921

DO - 10.2174/1568026619666190510091921

M3 - Article

VL - 19

SP - 892

EP - 897

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 11

ER -